Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only

Add time:08/31/2019    Source:sciencedirect.com

BackgroundIn patients suffering from major depressive disorders (MDD), improvements in MDD are related to increased activation of brain-derived neurotrophic factor (BDNF), an endogenous protein that facilitates neural functioning. To treat patients suffering from severe MDD, electroconvulsive therapy (ECT) is considered an efficacious and safe intervention, though the impact of ECT on plasma BDNF levels has thus far barely been investigated. The aim of the present study was therefore to assess plasma BDNF levels and depression of patients suffering from severe MDD treated with additional ECT compared to patients treated with citalopram only.

We also recommend Trading Suppliers and Manufacturers of ect protein (cas 136111-12-1). Pls Click Website Link as below: cas 136111-12-1 suppliers

Prev:Combining ECT with pharmacological treatment of depressed inpatients in a naturalistic study is not associated with serum BDNF level increase
Next:Further improving the cognitive effect profile of electroconvulsive therapy (ECT): The case for studying carbamylated erythropoietin☆)